Compare Moody's Corporation (MCO) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Natera Inc. Common Stock — how do they compare? Moody's Corporation trades at $477.87 (market cap $80.14B), while Natera Inc. Common Stock trades at $402.15 (market cap $57.03B). The key difference: Moody's Corporation is the larger of the two by market cap, and Moody's Corporation pays a 0.89% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 133 Days and Natera Inc. Common Stock for 0 Days on average.
| MCO | NTRA | |
|---|---|---|
Market Cap | $80.14B | $57.03B |
Volume | 829,155 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $539.61 | $425.64 |
52-Week Low | $412.23 | $179.42 |
Typical Hold Time | 133 Days | 0 Days |
Enterprise Value | $86.17B | $56.18B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moody's Corporation (MCO) trades at $464.13, down 1.35% on the day, yet maintains a bullish technical outlook with strong fundamental performance. The company reported Q2 2026 EPS of $4.68, beating expectations, and exhibits robust profitability with a 34.25% net income margin. Recent strategic moves include a minority stake in Philippine Rating Services Corporation to bolster Asia-Pacific presence, as reported by Business Wire on September 14, 2026.
MCO presents a compelling investment case driven by earnings momentum and high analyst conviction, with a consensus price target of $536.40 implying 15.6% upside. Key risks include elevated valuation multiples and sensitivity to credit cycle fluctuations. The stock's outlook remains positive, supported by consistent revenue growth and strategic expansions.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
